|
||||||||
|
|
|
|
|
|
|
||
|
|
|||||||
 |
  |
|||
Read about the latest news from qd Solutions. qd Tips: Clinical Trials News: |
Halting Bone-Building Osteoporosis Drug Use Cuts Risk for Additional Atypical Femur Fracture in HalfSAN FRANCISCO, Feb. 8, 2012 /PRNewswire-USNewswire/ -- There is growing evidence that supports an association between atypical fractures of the femur – a rare break of the thigh bone, typically without trauma – and the use of...
Posted on 8 February 2012 | 4:45 pm Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All EndpointsPhase 3 Studies of Eliglustat Tartrate Fully Enrolled CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 8, 2012 - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today four-year follow-up data from patients enrolled in the phase 2 clinical...
Posted on 8 February 2012 | 4:38 pm Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic PainAvanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain ALISO VIEJO, Calif., Feb. 8, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc....
Posted on 8 February 2012 | 4:20 pm Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I DisorderNEW YORK & BUDAPEST, Hungary--(BUSINESS WIRE)--Feb 8, 2012 - Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from a Phase III clinical trial of cariprazine (RGH-188), an investigational...
Posted on 8 February 2012 | 1:23 pm Pivotal Study Published in JAMA Confirms Potential of Novartis Candidate Vaccine Bexsero to Help Protect Infants Against Devastating Meningococcal Serogroup B DiseaseData previously presented at ESPID annual meeting add to the body of evidence showing that Bexsero can help protect all vulnerable age groups Study including more than 1,800 infants showed Bexsero induces robust...
Posted on 8 February 2012 | 12:30 pm |
|